Laurus Labs Ltd

Laurus Labs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Laurus Labs Ltd

₹ 1,228 1.81%
08 May - close price
lauruslabs.com BSE: 540222 NSE: LAURUSLABS
About

Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership
position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (including High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing.
Laurus employs 6,500+ people, including around 1,050+ scientists, at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. [1]

Key Points

Business Segments
1) Generic API (46% in 9M FY25 vs 41% in FY22): [1] [2] The company has one of the largest HiPotent API manufacturing capacities in India and is the world's leading third-party supplier of antiretroviral APIs. Its portfolio includes antiretrovirals, oncology, steroids, hormones, and cardiovascular APIs, serving global generic pharmaceutical companies. Segment revenue declined by 3% YoY in 9M FY25 due to ARV capacity reallocation towards high-yield, long-term business opportunities. [3] [1]

Website BSE NSE
  • Market Cap ₹ 66,311 Cr.
  • Current Price ₹ 1,228
  • High / Low ₹ 1,238 / 576
  • Stock P/E 74.6
  • Book Value ₹ 98.2
  • Dividend Yield 0.16 %
  • ROCE 17.7 %
  • ROE 18.2 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 17.4%

Cons

  • Stock is trading at 12.5 times its book value
  • The company has delivered a poor sales growth of 7.19% over past five years.
  • Company has a low return on equity of 10.3% over last 3 years.
  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 Nifty Pharma Nifty Midcap 100

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
1,381 1,182 1,224 1,195 1,440 1,195 1,224 1,415 1,720 1,570 1,653 1,778 1,812
1,095 1,015 1,037 1,014 1,198 1,024 1,045 1,130 1,300 1,187 1,250 1,298 1,299
Operating Profit 286 167 188 181 241 171 178 285 421 382 403 480 512
OPM % 21% 14% 15% 15% 17% 14% 15% 20% 24% 24% 24% 27% 28%
2 4 2 2 19 3 5 9 59 10 27 6 12
Interest 53 39 42 51 50 49 53 58 56 52 40 39 40
Depreciation 87 91 93 98 102 106 108 106 110 117 120 121 122
Profit before tax 147 41 54 35 107 18 23 131 312 224 270 327 361
Tax % 27% 30% 27% 27% 30% 34% 22% 31% 25% 28% 28% 22% 22%
105 27 37 23 75 13 20 93 233 162 194 252 282
EPS in Rs 1.91 0.46 0.69 0.43 1.40 0.23 0.37 1.71 4.33 3.02 3.61 4.66 5.17
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
1,327 1,778 1,905 2,056 2,292 2,832 4,814 4,936 6,041 5,041 5,554 6,813
1,126 1,415 1,497 1,642 1,935 2,266 3,262 3,512 4,448 4,261 4,499 5,035
Operating Profit 200 362 408 414 357 565 1,552 1,424 1,592 779 1,055 1,778
OPM % 15% 20% 21% 20% 16% 20% 32% 29% 26% 15% 19% 26%
34 4 32 29 15 5 23 14 6 24 75 55
Interest 106 111 100 80 88 90 68 102 165 183 216 171
Depreciation 62 86 106 125 164 187 205 251 324 385 430 480
Profit before tax 67 169 234 237 120 294 1,301 1,084 1,109 236 484 1,182
Tax % -2% 21% 19% 29% 22% 13% 24% 23% 28% 29% 27% 25%
68 134 190 168 94 255 984 832 793 162 358 890
EPS in Rs 8.81 16.97 3.60 3.16 1.76 4.77 18.33 15.40 14.67 2.98 6.64 16.46
Dividend Payout % 0% 2% 8% 9% 17% 10% 11% 13% 14% 27% 18% 7%
Compounded Sales Growth
10 Years: 14%
5 Years: 7%
3 Years: 4%
TTM: 23%
Compounded Profit Growth
10 Years: 21%
5 Years: -2%
3 Years: 4%
TTM: 178%
Stock Price CAGR
10 Years: %
5 Years: 20%
3 Years: 55%
1 Year: 109%
Return on Equity
10 Years: 17%
5 Years: 15%
3 Years: 10%
Last Year: 18%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 16 16 106 106 106 107 107 107 108 108 108 108
Reserves 640 774 1,225 1,377 1,452 1,663 2,490 3,244 3,930 4,003 4,365 5,192
888 1,094 842 980 1,036 1,079 1,482 1,777 2,015 2,577 2,764 2,518
345 339 481 554 737 901 1,671 1,840 1,608 1,699 2,099 2,693
Total Liabilities 1,888 2,224 2,653 3,017 3,331 3,750 5,751 6,968 7,660 8,387 9,336 10,511
801 1,021 1,230 1,481 1,629 1,726 2,171 2,652 3,409 3,890 4,123 4,371
CWIP 110 70 143 163 110 67 362 813 551 423 458 773
Investments 7 7 3 3 3 3 3 31 50 124 233 309
970 1,126 1,277 1,369 1,589 1,953 3,214 3,472 3,651 3,950 4,521 5,058
Total Assets 1,888 2,224 2,653 3,017 3,331 3,750 5,751 6,968 7,660 8,387 9,336 10,511

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
-65 182 332 342 298 347 733 911 994 666 602
-397 -312 -289 -384 -253 -221 -941 -914 -997 -822 -680
486 103 -54 42 -45 -128 255 30 -27 250 39
Net Cash Flow 24 -27 -10 1 -0 -1 47 27 -30 93 -39
Free Cash Flow -447 -144 55 -49 44 125 49 34 6 -10 61
CFO/OP -24% 59% 94% 98% 91% 68% 62% 77% 80% 99% 70%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 78 91 109 101 113 102 99 100 96 120 132 115
Inventory Days 210 176 186 201 201 234 266 293 222 277 285 317
Days Payable 102 90 96 107 144 159 199 146 94 158 141 170
Cash Conversion Cycle 186 178 199 195 170 177 166 247 224 240 276 263
Working Capital Days -0 19 3 -11 6 15 43 43 59 42 43 58
ROCE % 14% 16% 16% 14% 8% 14% 40% 26% 23% 7% 9% 18%

Insights

In beta
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
API Reactor Capacity
KL

Log in to view insights

Please log in to see hidden values.

Login
Finished Dosage (FDF) Capacity
Billion Units/Year
Cumulative DMF Filings
Number
Cumulative ANDA Filings (US)
Number
Fermentation Capacity
KL
Total R&D and Quality Personnel
Number
CAR-T Therapy Successful Infusions (NexCAR19)
Number
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

1 Recently
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
27.20% 27.20% 27.18% 27.18% 27.18% 27.18% 27.62% 27.62% 27.60% 27.60% 27.49% 27.49%
22.52% 24.03% 25.39% 25.98% 25.67% 26.08% 25.56% 25.51% 25.70% 26.17% 26.52% 25.82%
10.36% 11.01% 11.13% 11.78% 13.56% 13.05% 12.74% 11.78% 11.94% 11.72% 12.42% 13.96%
39.93% 37.75% 36.30% 35.07% 33.59% 33.69% 34.09% 35.09% 34.78% 34.52% 33.57% 32.73%
No. of Shareholders 4,17,9774,02,6403,82,8803,56,8303,24,0593,09,0632,92,2142,92,9052,80,2232,83,6782,80,7562,92,281

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls